CSPIA
TEVA icon

Cary Street Partners Investment Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13
Closed -$128 – 1689
2023
Q3 		$128 Buy
+13
New +$121 ﹤0.01% 1842
2023
Q2 		– Sell
-750
Closed -$6.64K – 1789
2023
Q1 		$6.64K Hold
750
– – ﹤0.01% 1248
2022
Q4 		$6.84K Buy
+750
New +$6.54K ﹤0.01% 1238
2020
Q4 		– Sell
-150
Closed -$1K – 811
2020
Q3 		$1K Buy
+150
New +$1.59K ﹤0.01% 958

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Cary Street Partners Investment Advisory's TEVA Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 13 shares — an estimated $128 sold.

Cary Street Partners Investment Advisory first reported a position in TEVA in Q3 2020 and held it in 4 quarters. The position peaked at $6.84K in Q4 2022. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 13 Teva Pharmaceuticals shares in Q4 2023, an estimated $128.
  • Cary Street Partners Investment Advisory first reported a position in Teva Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Teva Pharmaceuticals position peaked at $6.84K in Q4 2022.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.